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HIV undergoes high rates of mutation and recombination during reverse transcription, but it is not known whether these events
occur independently or are linkedmechanistically. Here we used a system of silent marker mutations in HIV and a single round
of infection in primary T lymphocytes combined with a high-throughput sequencing andmathematical modeling approach to
directly estimate the viral recombination andmutation rates. From>7 million nucleotides (nt) of sequences fromHIV infec-
tion, we observed 4,801 recombination events and 859 substitutionmutations (1.51 and 0.12 events per 1,000 nt, respectively).
We used experimental controls to account for PCR-induced and transfection-induced recombination and sequencing error. We
found that the single-cycle virus-inducedmutation rate is 4.6 105 mutations per nt after correction. By sorting of our data
into recombined and nonrecombined sequences, we found a significantly higher mutation rate in recombined regions (P 0.003
by Fisher’s exact test). We used a permutation approach to eliminate a number of potential confounding factors and confirm
that mutation occurs around the site of recombination and is not simply colocated in the genome. By comparing mutation rates
in recombined and nonrecombined regions, we found that recombination-associated mutations account for 15 to 20% of all mu-
tations occurring during reverse transcription.
The development of a genetically diverse quasispecies is one ofthe hallmarks of HIV infection. Genetic diversity underpins
the ability ofHIV to evolve resistance to antiretroviral therapy and
to successfully evade the immune system. Viral diversity increases
rapidly during initial infection (1) and is driven by mutation, re-
combination, and population size. Mutations are introduced pri-
marily during reverse transcription by the error-prone reverse
transcriptase (RT) enzyme (2) or by host cellular defense mecha-
nisms (3, 4). Thesemutations can then be shuffled within the viral
quasispecies by retroviral recombination, which relies on the co-
packaging of two genetically distinct RNA genomes (for a review,
see references 5–9). While the dimer initiation sequence (DIS) is
not critical for HIV replication in primary cells (10–12), the DIS is
important to facilitate the recombination process, presumably by
bringing genomic RNA sequences into close proximity during vi-
rion assembly and viral cDNA synthesis (13–17). Retroviral re-
combination occurs during reverse transcription when the RT
enzyme switches between strands of the two copackaged RNA
genomes to produce a chimeric DNA molecule (5–7, 18).
Whether retroviral mutation is linked with recombination has
been a subject of debate for decades, and numerous studies have
measured HIV mutation and retroviral recombination rates in
vitro and in cell culture (2, 19–31). Nevertheless, the question of
whether mutation and recombination are associated has not been
resolved directly due to numerous inherent technical difficulties.
To assess retroviral recombination, many studies utilize PCR to
amplify and to clone out the engineered reporter genes within the
retroviral vectors (or intersubtype HIV constructs) from the in-
fected cells, which is followed by expression of cloned sequences in
bacteria to indirectly assess the recombination andmutation rates
(32–34). Others have taken advantage of retroviral vector or re-
porter systems, in which the expressions of reporter genes (such as
fluorescent proteins, cell surface markers, and/or antibiotic resis-
tance genes) were used to select cells containing recombined viral
genomes for recombination and mutation analyses (28–31, 35–
39). As coexpression of reporter gene products in a single cell is
needed to identify recombination events, these systems generally
use a low multiplicity of infection (MOI) to avoid dual infection
introducing experimental bias (28–39).However, as these systems
require expression of the gene products, natural mutation events
or recombination events that lead to nonproductive expression of
reporter genes will be unaccounted for. It would have been advan-
tageous if recombination and mutation rates could be estimated
directly from the newly synthesized and/or integrated viral cDNA
that is independent of the MOI. Furthermore, as those studies
depend on PCR to amplify specific genomic sequences for recom-
bination and/or mutation analyses (28–30), the potential of PCR-
induced recombination and mutation must be controlled for to
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limit overestimation of these two retroviral biological processes
(40).
Using a transfection approach to generate heterozygousHIV to
assess retroviral recombination, we have previously shown that
HIV recombination does not randomly occur throughout the vi-
ral genome (20, 40). Based on the observed recombination events
in HIV gag, we have found that HIV-1 undergoes 1.35  103
recombination events per nucleotide (REPN) per replication cycle
(20). It is estimated that HIV-1 has a mutation rate that produces
approximately 0.34mutations per replication cycle (2, 19, 40, 41).
Consequently, mutation and recombination associate relatively
infrequently, and a large amount of sequencing data across the
HIV genome is needed to determine whether recombination and
mutations are linked. While reporter systems that can generate
large quantities of data have been developed to measure either
mutation rates or recombination rates on a nonviral sequence (30,
35, 36, 38, 42–45), these systems, however, cannot simultaneously
measure both recombination and mutation rates. Furthermore,
these systems measure rates within foreign nonviral gene se-
quences. As in vitro studies have shown that template sequence
and structure are important determinants of these processes (46,
47), the most accurate measurements will be derived from direct
sequencing of the viral genome (20). However, before the advent
of next-generation sequencing technology, generation of the large
amounts of sequencing data required to answer this question was
not feasible.
We have previously described a method to quantify the rate of
recombination by direct sequencing of the HIV-1 genome within
infected primary T lymphocytes (20, 40). This system addresses
several issues that can otherwise bias the analysis of mutation and
recombination rates using conventional approaches. First, al-
though recombination is most easily measured by using highly
divergent strains of HIV (as recombination can be observed only
through the mixing of genetic marker points), the rate of recom-
bination is greatly affected by the overall homology between ge-
nomes and processivity of RT (15, 16). Thus, recombination rate
measurements using highly divergent HIV strains do not reflect
the recombination occurring between highly relatedmembers of a
viral quasispecies found within an infected individual (48). Our
system addresses this issue by measuring recombination between
two closely related HIV-1 genomes that differ by silent mutations
found in naturally occurring HIV sequences, and these HIV se-
quences display identical replication kinetics in primary T lym-
phocytes (20). Second, by sequencing of viral cDNAs that are pro-
duced within 24 h of infection (with the fusion inhibitor T-20
supplied at 6 h postinfection to block secondary infection), all
HIV RT mutations and recombination that may lead to nonpro-
ductive infection will also be accounted for. Our previous work
also showed that a low MOI is not vital for this type of recombi-
nation analysis and does not yield intervirion recombination or
homologous recombination of plasmid DNA from transfection
that may bias data interpretation (20). Third, we have developed
experimental and analytical tools to account for artifacts that can
compromise analysis. For example, the impact ofmultiple recom-
bination events between two marker points (20), recombination
during cotransfection of plasmids, and PCR-induced recombina-
tion (40)must be all minimized and controlled for in any analysis.
Similarly, any analysis must take into account the possibility that
coincident high or low rates of mutation and recombination
(without the rate of mutation being specifically increased at sites
of recombination) can lead to a spurious association.
In this study, we have utilized a system of marker sites intro-
duced into HIV-1 to infect primary T lymphocytes, followed by
high-throughput sequencing. We have found that the previous
estimate of the nucleotide substitution rate closely matched our
calculated error rate of 4.6  105 using direct sequencing and
observed a significantly higher mutation rate in recombined re-
gions. We eliminated a number of potential causes for this associ-
ation to demonstrate a direct association between the processes of
recombination andmutation.We show that 15 to 20%of the total
mutations are associated with recombination.
MATERIALS AND METHODS
Molecular clones. The wild-type (WT) HIV-1 plasmid used was pDRNL
(AD8) (49). The marker (MK) plasmid [pDRNL(AD8)GagPolMarker]
was created by introducing 15 and 35 genetic marker points by silent
transition mutation in the gag and pol genes of pDRNL(AD8), respec-
tively. pDNRL(AD8) is an R5-tropic strain of HIV and thus infects the
activated/memoryT-cell lymphocyte subset (50). This created a total of 46
intervals spaced an average of 53.5 nucleotides (nt) apart (range, 17 to 155
nucleotides;median, 47 nucleotides), where recombination andmutation
could be simultaneously measured. The marker sites were chosen on the
basis that theywere (i) silentmutations in the third position, (ii) located in
adjacent codons, and (iii) A¡Gmutations observed in the HIV sequence
database (HIV SequenceCompendium [http://www.hiv.lanl.gov/]). Only
four markers contained mutations in nonadjacent codons. In addition,
the first and last markers in pol contained silent, but non-A¡G, muta-
tions and introduced the XhoI andNotI restriction sites, respectively, into
the genome. Twomutations in adjacent codons were used so that recom-
bination could be distinguished from mutations introduced during the
PCR or sequencing reactions. We reasoned that A-to-Gmutations would
have the least impact on the RNA structure, as U can base pair with both
A andG inRNA.Consequently, the introduction of A-to-Gmarker points
does not grossly disrupt base pairing within RNA structure regions. Nev-
ertheless, we did not modify regions of the HIV-1 genome with known
functional secondary structure, and we preferentially modified regions of
the genome containing these mutations as natural polymorphisms (HIV
Sequence Compendium [http://www.hiv.lanl.gov/]). The MK plasmid
was constructed, using standard molecular cloning techniques, from two
regions corresponding to gag and pol thatwere designed electronically and
synthesized chemically. The 14-day replication kinetics of marker virus
was indistinguishable from that of WT virus, and no protein or known
RNA sequence elements were changed.
Viruses. Homozygous virus was produced by transfection of 293T
cells with either theWT orMK pDRNLAD8 plasmid. In general, a total of
3 g of plasmid DNA containing proviral HIV genomes was used to
transfect 293T cells for the production of HIV particles. Heterozygous
virus was produced by cotransfection of equal masses of WT and MK
pDRNLAD8 plasmids into 293T cells. When equal amounts of two
HIV plasmids are cotransfected, copackaging of RNA into virions is ran-
dom (13). Consequently, we expected 50% heterozygous virions, 25%
homozygous WT virions, and 25% homozygous marker virions. Trans-
fections were carried out with polyethylenimine (PEI; Polysciences), and
transfection efficiencies were measured by using a reverse transcriptase
assay. While recombination has been observed during transfection under
certain experimental conditions (51–53), we have previously shown that
these transfection conditions do not yield observable recombination (20).
Furthermore, we have also converted the virion-associated RNA to cDNA
for direct sequencing, which showed that transfection-induced recombi-
nation (TIR) events had a negligible influence on our results (see below).
At 36 h posttransfection, virus-containing medium was harvested, clari-
fied by centrifugation at 1,462 g for 30 min, and then passed through a
0.45-m filter to remove cellular debris. Purified virus was concentrated
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by ultracentrifugation at 100,000 g through a 20% sucrose cushion and
stored at 80°C. Virus was treated with 90 units/ml Benzonase (Sigma)
for 15 min at 37°C to remove contaminating plasmid DNA before use.
Infections. Stimulated peripheral blood lymphocytes (PBLs) from 3
separate blood donors (patients) were infected with an equal mass of
either homozygous or heterozygous virus (which contained a mix of ho-
mozygous and heterozygous viruses), as determined by an HIV-1 antigen
(p24 CA) micro-enzyme-linked immunosorbent assay (ELISA) (Virono-
stika). In this experimental setup, the ability to measure recombination is
not affected by theMOI.Using viral cDNA synthesis as a surrogatemarker
for successful infection, retrospective analysis showed the averageMOI to
be 0.5 in these peripheral blood mononuclear cells (PBMCs). Efficient
removal of plasmidDNA by Benzonase treatment was confirmed for each
sample by using quantitative PCR (qPCR) targeting the ampicillin gene.
Only virus preparations where the infection had no or insignificant back-
ground PCR signals (5% of wild-type infection) were used in subse-
quent infection and sequencing experiments (Table 1). We note that any
potential carryover plasmid DNA would have the effect of reducing the
observed HIV recombination and mutation. At 6 h postinfection, 10
g/ml T-20 (Roche) was added to the cells to prevent second-round rep-
lication. At 24 h postinfection, cells were pelleted and lysed in PCR lysis
buffer containing 1 PCR buffer (Roche) with 0.5% (vol/vol) Triton
X-100, 0.5% (vol/vol) NP-40, and 75g/ml proteinase K (Roche). A total
of 1  106 cells were lysed per 100 l of PCR lysis buffer. Samples were
incubated at 56°C for 1 h before proteinase K was inactivated at 95°C for
10 min; samples were then stored at20°C. Lysates were diluted 10 in
PCR grade water before quantification by quantitative PCR.
Primers. PCR primers were designed to span the 46 intervals as 14
overlapping amplicons of roughly 350 nucleotides. PCR primers were
designed against regions that were identical between the WT and MK
plasmids according to the manufacturer’s directions (Finnzymes).
Primers used are as follows: G1 sense (5=-GGTGCGAGAGCGTCGG
TATTAAG-3=), G1 antisense (5=-CTGTGTCAGCTGCTGCTTGCTG-
3=), G2 sense (5=-TCCTCTATTGTGTGCATCAAAGGATAGATG-3=),
G2 antisense (5=-CCACTGTGTTTAGCATGGTATTTAAATCTTGTG-
3=), G3 sense (5=-CAAATGGTACATCAGGCCATATCACCTAG-3=), G3
antisense (5=-CTGCATGCACTGGATGCAATCTATC-3=), G4 sense (5=-
GAAGGAGCCACCCCACAAGATTTA-3=), G4 antisense (5=-GGTTCCT
TTGGTCCTTGTCTTATGTCCAG-3=), G5 sense (5=-GGAAGTGACAT
AGCAGGAACTACTAG-3=), G5 antisense (5=-AGTCTTACAATCTGGG
TTCGCATTTTGG-3=), G6 sense (5=-AAACTCTAAGAGCCGAGCAAGC
TTC-3=), G6 antisense (5=-TGCCCTTCTTTGCCACAATTGAAACAC-3=),
P1 sense (5=-GCAGGAGCCGATAGACAAGGAACT-3=), P1 antisense (5=-T
AAAGTGCAGCCAATCTGAGTCAACAG-3=), P2 sense (5=-AGAAATCTG
CGGACATAAAGCTATAGG-3=), P2 antisense (5=-GGAGTATTGTATGG
ATTTTCAGGCCCAA-3=), P3 sense (5=-GTAAAATTAAAGCCAGGAATG
GATGGC-3=), P3 antisense (5=-GAAAAATATGCATCGCCCACATCCAG-
3=), P4 sense (5=-TGTGGGCGATGCATATTTTTCAGT-3=), P4 antisense
(5=-ATGGAGTTCATAACCCATCCAAAGGAATG-3=),P5 sense (5=-CACC
AGCAATATTCCAGTGTAGCATG-3=), P5 antisense (5=-CTTTAATCCCT
GCATAAATCTGACTTGCC-3=), P6 sense (5=-GAACTCCATCCTGATAA
ATGGACAGTACAG-3=), P6 antisense (5=-TTAAATGGCTCTTGATAAAT
TTGATATGTCCATTG-3=), P7 sense (5=-CCACTAACAGAAGAAGCAGA
GCTAGAACTG-3=), P7 antisense (5=-CAGGTGGCTTGCCAATACTCTG
TC-3=), P8 sense (5=-AGGGTGCCCACACTAATGATGTGAAAC-3=), P8
antisense (5=-AGTCTTCTGATTTGTTGTGTCCGTTAGG-3=), AMP sense
(5=-AACTCGCCTTGATCGTTGGG-3=), and AMP antisense (5=-TGTTGC
CATTGCTACAGGCATC-3=).
Quantitative PCR. Quantitative PCR was performed on an MX3000
instrument (Stratagene). Reverse transcription products were assessed by
using the HIV-1-specific primer pair M661/M667 (54), and background
plasmid levels were assessed by using primers directed against the ampi-
cillin resistance gene (AMP) (see the primer list, above). Each PCR mix-
ture contained 1 Brilliant II master mix (Stratagene), 400 nM each
primer, and 5 l cell lysate in a 15-l reaction mixture volume. For viral
cDNA estimation, PCR conditions were an initial denaturation step at
95°C for 15min followed by 40 rounds of cycling at 95°C for 10 s and then
60°C for 30 s. Samples were compared to ACH2 cell standards.
PCR.With amplicon generation for next-generation sequencing, PCR
conditions were optimized to reduce the formation of artificial recombi-
nants by using amethod outlined by Smyth et al. (40). PCRmixtures were
titrated to contain 2,500 copies of template DNA, 1 HF buffer
(Finnzymes), 200 Mdeoxynucleoside triphosphate (dNTP), 1 M each
primer, and 0.3 U of Phusion DNA polymerase (Finnzymes) in a 15-l
total reaction mixture volume. Plasmid DNA was titrated in cellular
lysates from uninfected PBLs so that the DNA complexity of the control
PCRs faithfully represented the experimental samples. PCRs were per-
formed in quadruplicate, and data were pooled to guard against PCR bias.
PCR cycling conditions were 98°C for 30 s followed by 29 cycles of 98°C
for 10 s and 72°C for 1 min.
Transfection-induced recombination. To assess the rate of transfec-
tion-induced recombination, RNAwas extracted fromheterozygous virus
by using phenol chloroform-based Tri reagent (Sigma-Aldrich), accord-
ing to themanufacturer’s recommendations, and reverse transcribed into
cDNA by using SuperScript III (SSIII) (Invitrogen Life Technologies) and
gene-specific primer GAG4(4195)R (5=-ACATTTCCAACAGCCCTTTT
TCCTAG-3=). To control for in vitro cell-free reverse transcription and
PCR-induced recombination, control samples consisting of homozygous
WT virus and homozygous MK virus were mixed in equal quantities
(based on p24 values) prior to RNA extraction and were reverse tran-
scribed in parallel with RNA extracted from heterozygous virus. Re-
verse transcription was performed in the presence and absence of
SSIII, with the latter condition providing a control for any plasmid
contamination carried over from transfection. Real-time PCR was
used to estimate viral cDNA copy numbers against a standard curve
based on plasmid pDRNL(AD8) by using primers GAG1(2945)F (5=-
GAGATGGGTGCGAGAGCGTC-3=) and GAG1(3314)R (5=-TGTGTC
AGCTGCTGCTTGCTG-3=). Twenty replicate wells containing 2,500 copies
of template viral cDNAwere amplifiedbyusingoptimizedPCRconditions to
reduce the formation of artificial recombinants, as outlined by Smyth et al.
(40).
454 sequencing. PCR amplicons spanning gag and polwere pooled for
each blood donor. Unique 6-nucleotide identifiers (barcodes) were then
individually attached by parallel tagged sequencing to allow multiplexing
of samples from different blood donors on the same sequencing run (55,
56). Single-stranded sequencing libraries were constructed from 1 g of
initial starting material by using the 454 library preparation kit (Roche)
according to the manufacturer’s directions. Libraries were quantified and
stored at 20°C until further use. Emulsion PCR and sequencing were
performed according to standard GS FLX titanium procedures. In order
TABLE 1 Removal of contaminating plasmid DNA by Benzonase
treatmenta
Sample Donor
Sample
type
No. of HIV
copies
No. of
ampicillin
copies % Background
1 JL10 Intervirion 13,250 163.3 1.23
2 JL10 Wild type 9,559 121.8 1.27
3 RS13 Intervirion 11,700 127.6 1.09
4 RS13 Wild type 1,746 29.56 1.69
5 WJ2 Intervirion 5,822 44.36 0.76
6 WJ2 Wild type 4,148 51.93 1.25
a Efficient removal of contaminating plasmid DNA by Benzonase treatment was
confirmed by qPCR quantification of HIV and ampicillin gene sequences using specific
primers and the same standard based on serial dilutions of the NL43 plasmid. HIV-
specific primers used were 5=-TTAAATGGCTCTTGATAAATTTGATATGTCCATT
G-3= (P7 sense) and 5=-CCACTAACAGAAGAAGCAGAGCTAGAACTG-3= (P7
antisense). Ampicillin-specific primers were 5=-AACTCGCCTTGATCGTTGGG-3=
(AMP sense) and 5=-TGTTGCCATTGCTACAGGCATC-3= (AMP antisense).
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to avoid excessive resampling of the sameDNA strand, the 454 library was
constructed from PCR products derived from at least 10 times more viral
cDNAmolecules than themaximumnumber of sequencing reads allowed
in a reaction. For each full 454 sequencing run, the 454 library consisted of
PCR products from 4,000 PCRs, with each reaction mixture containing
2,500 templates for amplification. This results in a 454 library consisting
of PCR products derived from 10 million original templates, with a max-
imumof 1million sequencing reads per 454 sequencing reaction. For PCR
products derived from every 2,500 copies of original template, only 10%
(250 copies) of its next-generation sequencing read was used for analysis
to minimize resampling of the same original sequence, which could bias
the estimation of the recombination and mutation rates.
Sequence alignment. Sequencing data were processed to remove the
6-nucleotide barcode and assigned to a sample only upon a perfect bar-
code match. To reduce the missense error rate of 454 sequencing, se-
quences were also removed if they were of poor quality (such as those
containing ambiguous nucleotides [“N=s”]) or not full length. All se-
quencing analysis was performed by using software custom written in
BioRuby (http://www.bioruby.org/). In order to count mutations and
other events, the sequences were aligned against the consensus sequence
of the wild-type andmarker-type versions of the amplicon (plus a margin
of 100 nucleotides on both ends of the amplicon) by using needle. The
parameters for needle were a gap-opening penalty of 3.0 and a gap exten-
sion penalty of 0.5. Segments which contained an ambiguous marker (a
mutation within the marker) were discarded from the analysis.
Measurement of recombination rate. The conversion of raw rates of
chimera formation into recombination events per nucleotide (REPN) and
statistical comparisons between recombination rates were performed by
using methods described previously by Schlub et al. (20). Briefly, recom-
bination was detected by monitoring the linking of marker points from
wild-type andmarker-type genomes into a single genome.However,mea-
suring the crude recombination rate by dividing the number of events by
the number of nucleotides can be misleading. Therefore, our approach,
which has been described in detail previously (20), takes into account a
number of factors inherent in the marker system.
First, multiple recombination events can occur between two marker
points. Consequently, all odd numbers of recombination events between
two markers (1, 3, 5, 7, 9, . . . ., etc.) will be counted as a single recombi-
nation event, while even numbers of recombination events between two
markers (2, 4, 6, 8, 10, . . . ., etc.) will go undetected.
Second, we infect cells using a mix of heterozygous and homozygous
virions (and in the latter, recombination will go undetected). Thus, we
directly estimate the proportion of heterozygous virions for each sample.
Third, the widths of our intervals vary substantially, and therefore, we
must take into account different likelihoods of multiple recombination
events.
Ourmathematical procedure accounts for these factors to estimate the
recombination rate within the experimental system. This estimated re-
combination rate minimizes the chi-square value:
2
i1
k Ei Oi2
Ei
where k is the number of intervals between markers and Ei andOi are the
expected and observed numbers, respectively, of detected recombinations
for interval i. The expected number of detected recombination events in
any given interval, Ei, is calculated as
E s 
j1
Li 12 
CLi, 2j 1r2j11 rLi 2j 1
where s is the number of heterozygous sequences, Li is the nucleotide
length of the interval, [(Li  1)/2] is the integer part of (Li  1)/2, and
C(Li,k) is the binomial coefficient for picking k unordered outcomes from
Li possibilities.
Estimatingmutation rate per recombination:method 1.To estimate
the background rate of mutation and the rate of mutation induced by
recombination, we consider the numbers of point mutations in intervals
with and those without recombination. Intervals derived from homozy-
gous virions do not display recombination regardless of RT template-
switching activity. Therefore, we initially limited ourselves to sequences
that are known to be derived from heterozygous sequences (sequences
which contain at least one observable recombination). The mutation rate
in heterozygous intervals without recombination, mb, provides an esti-
mate of the background mutation rate alone. The mutation rate per nu-
cleotide in intervals with recombination,mr, then represents the cumula-
tive effect of background mutation and mutation induced from the
recombination event. Thus,mrmb p/L, where p is the mutation rate
per recombination and L is the length of the interval. Asmr andmb can be
calculated directly from the data and L is known, p can be calculated.
Despite the large data set, as mutation rates and recombination rates are
relatively low, mutation rates for individual intervals may have large
amounts of variation by random chance alone. Thus, mutation rate cal-
culations will not be informative if calculated on a per-interval basis. To
overcome this, we calculate mr and p from the cumulative mutation rate
over all heterozygous intervals with and without recombination and in
this case replace L with the average length of intervals displaying recom-
bination.
Estimating mutation rate per recombination: method 2. Method 1
estimates the backgroundmutation rate per nucleotide and an additional
mutation rate per recombination event. However, thismethod uses only a
fraction of the available data (sequences known to be heterozygous). Ad-
ditionally, method 1 does not compensate for recombination events oc-
curring at a frequency of	1 per interval (although this is estimated to be
minimal). To adjust for these factors, we developed a second method to
measure mutation rates, as described below.
To estimate the background rate of mutation and the rate of mutation
induced by recombination, we consider the numbers of point mutations
in intervals with recombination (N1), heterozygous intervals without re-
combination (contains a recombination somewhere on the sequence)
(N2), and intervals of unknown ancestry (no recombination on the re-
mainder of the sequence) without recombination (N3). Thus, for each
interval, over all sequences,
N1mI1 p
x
R
s1
N2mI2 p
y
1 R
s2
N3mI3
y
1 R
s3 x ys4
wherem is the background rate of mutation; I1, I2, and I3 are the numbers
of informative nucleotides in intervals with recombination, heterozygous
intervals without recombination, and intervals of unknown ancestry
without recombination, respectively; p is the rate of mutation per recom-
bination; R is the probability of observing a recombination over that in-
terval; s1 and s2 are the numbers of intervals with recombination and
heterozygous intervals without recombination, respectively; and s3 and s4
are the estimated number of intervals derived from heterozygous virions
that have no recombination along the entire sequence (and are thus of
unknown heterozygous/homozygous ancestry) and the estimated num-
ber of homozygous intervals, respectively, and where x  P1  3P3 
5P5 . . . . and y 2P2 4P4 6P6 . . . ., with Pi being the probability
of i recombinations occurring in a single interval. Thus, the terms x/R and
y/(1 R) represent the expected numbers of recombinations per interval
in heterozygous intervals with and without recombination, respectively.
The term (x  y) represents the number of recombinations expected to
occur in a homozygous interval (where recombination is unobservable).
To calculate a single mutation rate per nucleotide and mutation rate
per recombination over all intervals, we optimize the expected values of
N1, N2, and N3 to minimize the summed square error to the observed
counts over all intervals. As N3 represents the majority of our data set,
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weighting ofN1,N2, andN3 errorsmay be employed to amplify their effect
on the mutation rate estimations. However, such weighting did not sub-
stantially change mutation rate calculations in this data set and did not
affect the conclusions drawn. Optimizations were performed in Matlab
(v7.1.0.124 [R14]; Mathworks Inc.) with the function fmincon.
Estimating mutation rate per recombination: subtracting controls.
As the mechanism for individual mutations and recombinations cannot
be determined, we cannot remove experimentally induced mutation
and/or recombination prior to the analysis and comparison of rates.
Rather, we estimate rates of mutation, recombination, and mutation per
recombination for the biological sample and then separately estimated
these rates for the controls. We then show that the contribution of exper-
imental mutation/recombination to themutation rate per recombination
is minimal. Specifically, by estimating the proportion of recombination
events attributable to experimental factors and their corresponding mu-
tations, we estimate that only 9 to 15% of the recombination-associated
mutation rate observed following infection could be due to experimental
factors. This was subtracted from the biological sample rate to estimate
the recombination-associatedmutation rate attributable to viral infection
processes only (RT, RNA polymerase II, and, potentially, host nucleic
acid-editing enzymes such as APOBEC3G). This rate is then used to cal-
culate the mutation rate per recombination for viral infection only.
Statistical analysis. Statistical andmathematical analyses were carried
out by usingGraphpad Prism andMatlab, respectively. Fisher’s exact tests
were used to compare overall rates of mutation. To eliminate the effect of
“coincident hot spots,” we developed a permutation approach to investi-
gate the relationship between mutation and recombination (see Fig. 3A
and B). In this approach, each sequence interval (the region between two
marker sites) was classified as recombined (R) or nonrecombined (NR).
The classification of R or NR was then randomly permuted (reshuffled)
10,000 times to generate the expected distribution of mutations within R
and NR intervals if mutation and recombination were not associated. To
avoid confounding variables, we reshuffled only within the same interval,
same amplicon, same direction of sequencing, and same patient. By com-
paring the observed difference in R and NR mutation rates with those
obtained from random reshuffling, we eliminated the confounding effects
of coincident hot spots and Simpson’s paradox.
RESULTS
Measurement of recombination and mutation. We used a sys-
tem of markers introduced into the HIV gag and pol genes to
simultaneously measure the rates of recombination andmutation
during a single round of replication (Fig. 1A). A total of 46 inter-
vals spaced an average of 53.5 nucleotides apart (range, 17 to 155
nucleotides; median, 47 nucleotides) were used. The positions of
these mutations were chosen due to their natural polymorphism
in the HIV database, and this marker HIV also has replication
kinetics identical to that of our parental wild-type control.
Heterozygous virus was produced by cotransfection of 293T cells
with an equal mass of WT and marker (MK) plasmids, leading
to a mixture of virions containing WT homozygous (25%), MK
homozygous (25%), and WT-MK heterozygous (50%) copack-
aged RNA genomes, as described previously (13, 14, 20). The ratio
of homozygous to heterozygous virions in ourHIV infection stock
was also internally monitored for each infection based on the fre-
quency of nonrecombinedWT andMK sequences (20). Thismix-
ture of heterozygous and homozygous viruses was used to sepa-
rately infect freshly stimulated T lymphocytes from three separate
blood donors. Following a single round of infection, viral DNA
was extracted, PCR amplified, and sequenced (Fig. 1B). As previ-
ously reported, we have chosen to use a high-fidelity and high-
processivity DNA polymerase (40), Phusion, which has a signifi-
cantly higher fidelity rate than those of other polymerases, with an
estimated error rate of 4.5 107 per base pair (57).
In addition to our experimental sample, we included a number
of controls that account for sequencing error and PCR-induced
recombination and mutation (Fig. 1D and E and Table 2). The
DNA control consisted of PCR amplification and subsequent se-
quencing of plasmid DNA (Fig. 1D and Table 2). This sample
allowed us to control for the rates of recombination and sequenc-
ing error during PCR amplification and 454 sequencing. Plasmid
DNA was titrated in cellular lysates from uninfected PBLs so that
the DNA complexity of the control PCRs faithfully represented
the experimental samples. The second control involved infecting
cells with a mixture of homozygous (containing identical copack-
aged RNA genomes) WT and MK viruses, before PCR amplifica-
tion and sequencing (Fig. 1E and Table 2). In this case, recombi-
nation during HIV reverse transcription is expected to occur at a
normal rate but effectively be “silent,” as the homozygous virus
simply recombines onto an identical RNA strand. However, re-
combinant chimeras betweenWT andMKDNA strands may still
occur during subsequent PCR amplification after cells are lysed.
Thus, the level of PCR-induced recombination in this sample
should occur at exactly the same rate as that during heterozygous
virus infection. This second recombination control also directly
monitors the levels of intervirion recombination events, demon-
strating that the MOIs used in these infections did not bias the
observed recombination rate (Table 2). Finally, this control incor-
porates the possibility of multiple rounds of infection, which are
not expected to occur due to the addition of fusion inhibitors 6 h
after infection and the termination of infection at 24 h postinfec-
tion.
In response to reviewer concerns, a further round of controls
was performed to assess whether transfection-induced recombi-
nation (TIR) might be occurring during the initial stage of trans-
fection of the plasmids. TIR might occur when the WT and MK
plasmids are cotransfected and undergo recombination in vitro.
To exclude this possibility, we sequenced the virus produced by
transfected cells (Fig. 1C and Table 3). Because this involved a
reverse transcription step performed on viral RNA, it is possible
that any recombination events observed in the viral sequences
may have arisen from reverse transcription rather than TIR.
Therefore, we included controlswhereWTandMKplasmidswere
transfected separately into cells, and the resultant homozygous
viruses were combined only for the stage of reverse transcription.
These assays showed that transfection of the two different plas-
mids did not result in more recombination than seen with reverse
transcription of homozygous virions, indicating very little or no
TIR (approximately 0.006  103 REPN, 0.5% of the total re-
combination rate) (Table 3). Moreover, the total level of recom-
bination seen was so low that even if all of these recombination
events were caused by TIR (and not by the reverse transcription
step), they would not account for any significant proportion of
recombination events seen in the data.
Under each experimental condition, six pairs of overlapping
gag PCR amplicons and eight pairs of overlapping pol PCR ampli-
cons were used to amplify the corresponding viral sequences.
These PCR amplicons cover all the marker points in gag and pol
and have an approximate length of 350 nucleotides, which is op-
timal for 454 pyrosequencing. Each PCR amplicon contains be-
tween 5 and 7 marker points and, hence, 4 to 6 intervals each for
our analysis.
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FIG 1 Measurement of recombination and mutation rates. (A) Schematic of the marker system. A marker plasmid (MK) was generated through the introduction of
silent markers into the gag and pol genes of wild-type (WT) HIV (shown as green dots). The positions of the amplicons are marked as red horizontal bars. (B)
Experimental infection.MKplasmid andWTplasmidDNAswere cotransfected into 293T cells to produce amixture of heterozygous andhomozygous virus. Viruswas
then used to perform a single round of infection in primary T cells. DNA was subsequently extracted for PCR and high-throughput sequencing. (C to E) Controls for
experimentally induced recombination andmutations. (C) The first control consisted of amplifying and sequencing of heterozygous virus reverse transcribed in vitro.
This control assesses the rate of recombinationoccurringduring cotransfectionof viral plasmid. (D)The second control involvedPCRamplificationof amixture ofMK
andWTplasmidDNAs to assess the rate ofmutation and recombination during amplification and sequencing. (E) Two separate transfections of either theWTorMK
plasmid were used to produce homozygous WT and MK viruses. These homozygous virus preparations were combined 50:50 and used to infect cells. Thus, any
recombinationduring reverse transcriptionoccurs onan identical strand (since the virus is homozygous) and is undetectable. The rate ofmutation is the sameas that for
the experimental sample, and only experimentally (PCR) induced recombination was measured. (F and G) Recombination and mutation rates in each region of the
experimental sample. The average rates that would produce this distribution are shown as dashed lines.
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Following sequencing and alignment, we obtained on average
3,364 sequences per interval (range, 1,290 to 6,889) for the exper-
imental sample. Each marker position was then classified as WT,
MK, or ambiguous (if it was not identical to either a WT or MK
sequence). Each interval between markers was then classified as
recombined (R) if adjacent markers were WT and MK, nonre-
combined (NR) if adjacent markers were identical, or ambiguous
if either adjacentmarker could not be classified.We calculated the
recombination rate using a method that takes into account the
proportion of homozygous sequences (where virally induced re-
combination cannot be detected) as well as the possibility of mul-
tiple undetectable recombination events betweenmarker sets (de-
scribed in detail in reference 20). From this, we estimated the
overall recombination rate in our experimental samples (1.51 per
1,000 nt) and in our controls (Fig. 1F and Table 2).
We next studied the rate of mutation in these samples (Fig. 1G
and Table 1). To avoid resampling of the viral cDNA, which could
lead to an inaccurate estimation of the mutation rate in the HIV
genome, 10-fold excesses of viral cDNAwere used as the templates
for 454 sequencing; i.e., 	10 million distinct viral cDNA tem-
plates were used for a complete run (1 million reads) of 454 se-
quencing. In the experimental sample, from a total of 7,180,712
informative nucleotides, we observed 859 mutations, giving an
overall mutation rate in of 0.120 per 1,000 nt. This mutation rate
represents the cumulative effect of experimentally induced “back-
ground” PCR and sequencing errors and the viral RT-induced
mutation. We estimated the background rate by amplifying and
sequencing a plasmid DNA with a 50:50 mix of the WT and MK
sequences in the presence of cell lysates from uninfected PBLs.
Here our sample consisted of 4,931,016 nt, from which we ob-
served 366 mutations, giving a mutation rate of 0.0742 per 1,000
nt (Table 2). We note that our background rate of substitution
mutations from PCR amplification and sequencing is signifi-
cantly lower than some other estimates, and this difference
likely reflects the high-fidelity nature of Phusion DNA poly-
merase in our analyses. In addition, removal of low-quality
sequencing reads (i.e., those containing ambiguous nucleo-
tides [“n”] or that were not full-length amplicons) also kept the
rate low. The mutation rate attributable to viral factors (in-
cluding RT, RNA polymerase II, and, potentially, host nucleic
acid-editing enzymes [e.g., APOBEC3G]) is the difference be-
tween the error rate in the biological sample and that for the
plasmid DNA control. This rate is 0.120 0.0742 0.0458 per
1,000 nt. This is similar to the rate of 1.4  105 to 4  105
previously estimated for HIV-1 (2, 19, 41).
Higher mutation rate in recombined intervals. In order to
test whether recombination was associated with mutation, we
compared the mutation rates in intervals where recombination is
and is not observed.We found a significantly highermutation rate
in recombined intervals than in nonrecombined intervals (0.181/
1,000 nt versus 0.117/1,000 nt; P  0.003 by Fisher’s exact test).
However, since our procedure involved PCR amplification, and
we have previously demonstrated that PCR-induced recombina-
tion occurs at a low but significant rate (20), it is possible that
PCR-induced recombination during sample preparation was re-
sponsible for the observed association between recombination
and mutation. To exclude this possibility, we analyzed control
infections where we infected cells with a 50:50mix of homozygous
WT and MK viruses. Because of the low rate of PCR-induced
recombination, we sequenced twice as many samples, leading to a
total of 15,407,974 informative nucleotides from control samples.
As previously described (40), the rate of PCR-induced recombi-
TABLE 2 Summary of mutation and recombination ratesa
Sample
Total no. of
nucleotides
No. of
recombination
events
Recombination
rate/1,000 nt
No. of point
mutations
Mutation
rate/1,000 nt
No. of
indels
Indel rate/
1,000 nt
DNA control 4,931,016 37 0.024 366 0.074 33,008 6.70
Homozygous control 15,407,974 338 0.050 1,830 0.119 98,281 6.38
Infection (total) 7,180,712 4,801 1.51 859 0.120 47,316 6.59
Total R sequences 297,908 4,801 NA 54 0.181 2,082 6.99
Total NR sequences 6,882,804 0 NA 805 0.117 45,234 6.57
NR sequences on NR strands 6,312,179 0 NA 762 0.121 41,659 6.60
NR sequences on R strands 570,625 0 NA 43 0.075 3,575 6.27
a For each sample, the number of informative nucleotides from recombined or nonrecombined intervals as well as the numbers of recombination events, point mutations, and
indels (frameshift errors) are indicated. We included controls for measuring the magnitude of recombination and mutation resulting from PCR and 454 sequencing: the DNA
control, where plasmid DNA was amplified and spiked with cellular lysates to control for any impact of these on amplification efficiency/fidelity, measuring PCR recombination
and mutation by PCR and 454 sequencing, and the homozygous control, where two homozygous virus infections (one MK and one WT) were combined after lysis and before PCR
amplification so that recombination during reverse transcription is silent and recombination during PCR is observable, measuring PCR recombination and mutation of viral cDNA
by 454 sequencing. The experimental infection samples are further broken up into recombined and nonrecombined sequences. The latter are also broken up into nonrecombined
sequences on recombined strands and on nonrecombined strands. NA, not applicable.
TABLE 3 Summary of mutation and recombination for the transfection
controla
Sample
Total no. of
nucleotides
No. of
recombination
events
Recombination
rate/1,000 nt
Transfection-induced
recombination control
22,600,749 58 0.006
SuperScript III control 3,261,995 4 0.005
DNA control 24,893,615 31 0.004
Heterozygous infection 6,558,479 4,243 1.59
a To exclude the possibility that recombination during transfection of plasmids is
biasing our results, we sequenced virus produced by transfected cells. This rate
measures the cumulative effect of transfection-induced recombination and the reverse
transcription step using SuperScript III (see Materials and Methods). To determine the
level of reverse transcription recombination using SuperScript III, we sequenced virus
produced by cells separately transfected with either MK plasmids or WT plasmids only,
which were mixed before reverse transcription. We also repeated the PCR control
(DNA control) for this assay and the experimental sample.
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nation in this sample (0.050 per 1,000 nt)wasmuch lower than the
cumulative effect of viral RT-induced and PCR-induced recom-
binationmeasured for heterozygous infection (1.51 per 1,000 nt).
PCR-induced recombination was associated with a higher muta-
tion rate (mutation rate of 0.537 per 1,000 nt inR sequences versus
0.118 per 1,000 nt in NR sequences; P 0.0001 by Fisher’s exact
test). Although the mutation rate was increased with PCR-in-
duced recombination, the overall rate of PCR-induced recombi-
nationwasmuch too low to account for the observed difference in
the heterozygousHIV infection samples; that is, correcting for the
sample size, we expect that around 3% of recombination events
are due to PCR error and that in our total sample, these PCR-
recombined regions would contain approximately 5 mutations
(including both background and recombination-associated mu-
tations). Thus,10% (5/54) of the total mutations in the recom-
bined regions could be attributed to PCR-induced recombina-
tion. Similarly, transfection-induced recombination accounted
for 0.5% of mutations when we sequenced the virion genomes
directly (Table 3) and is too low to contribute to the observed
rates.
Although we observed an overall higher rate of mutation in
recombined regions, this could have occurred for a number of
potential reasons. First, the apparent association between muta-
tion and recombination could have been artificially created by
pooling data over the various intervals and sequences from vari-
ous amplicons. This could occur in a scenario where coincident
recombination andmutation hot spots led to higher incidences of
both mutation and recombination at particular segments, even
though recombined intervals had the same mutation rate as non-
recombined intervals within the segment (Fig. 2A, yellow box).
This would be an example of the so-called “Simpson’s paradox”
(58). A second potential confounder is the effect of “error-prone
cells” or “error-prone strands” driving the observed association;
that is, if some cells, RT enzymes, or viral RNA strands produce a
particularly high rate of both mutation and recombination in any
particular set of amplicons, mutation and recombination will ap-
pear to be associated, even if it is only because the mutation rate is
higher all along the error-prone strand and not higher in all re-
combined intervals on the strand in general (Fig. 2B, light orange
boxes).
Mutation is associated with recombination. To eliminate the
effect of coincident hot spots, we developed a permutation test
(Fig. 3A and B; see alsoMaterials andMethods). In this approach,
recombination classification (R or NR) for each sequence interval
(the region between two markers) was randomly permuted to
generate the expected distribution of mutations within R and NR
intervals if mutation and recombination were not associated. By
comparing the empirical difference in R and NR mutation rates
with those obtained from permutation, the probability of ran-
domly observing an association between recombination and mu-
tation, assuming no underlying association, can be eliminated
with the confounding effects of coincident hot spots, and Simp-
son’s paradox can be eliminated. From10,000 reshuffling runs, we
observed only 51 runs where the difference in mutation rates was
as great as that observed experimentally. Thus, the association
between mutation and recombination is significant (P  0.0102
by two-tailed test) and is not affected by the confounding effects of
coincident hot spots.
In the case of error-prone strands, the confounding effect of
high mutation and high recombination rates of a subset of se-
quences would lead to a spurious association between recombina-
tion andmutation. In this scenario, we expect that sequences with
a high recombination rate would also have a high mutation rate
(Fig. 2B). Therefore, the mutation rate should be on average
higher in recombined strands (in both recombined and nonre-
combined intervals) than it is in nonrecombined strands. To in-
vestigate this, we classified all NR intervals into those on a strand
with recombination elsewhere (NRR) and those on a strand with
no recombination (NRNR). If the association between mutation
and recombination is due to error-prone strands, we expect that
the mutation rate of NRR would be higher than that of NRNR.
Alternatively, if the association between recombination and mu-
tation is not due to error-prone strands, we expect that the muta-
tion rate of NRR would be less than or equal to that of NRNR. The
case of the mutation rate of NRR being less than that of NRNR can
occur because NRR intervals are truly nonrecombined (they are
known to be derived from a heterozygous infection, as they have
an observed recombination elsewhere), whereas NRNR will be a
mix of heterozygous intervals without recombination, homozy-
gous intervals without recombination, and homozygous intervals
with undetectable recombination. The homozygous intervals with
undetectable recombination will increase the mutation rate in
FIG 2 Association between recombination and mutation. An experimental
association between mutation and recombination may be observed due to
either coincident hot spots (A) or error-prone strands (B), even though there
is no realmechanistic association. (A)A coincident hot spot scenario can occur
if there is a region of the genome with both high mutation and high recombi-
nation rates (yellow box). In this scenario, overall, we see that 2 of the 5
recombined segments (R) (40%) have mutations, and only 4 of the 13 (31%)
nonrecombined segments (NR) have a mutation. However, this apparent as-
sociation is due simply to the high mutation and recombination rates in the
yellow region. There is no highermutation rate in R segments when individual
regions are analyzed separately; that is, there are no mutations in the recom-
bined regions outside the hot spot and an equal rate of recombination in R and
NRwithin the hot spot (i.e., 2/3 segments havemutations for both R andNR).
(B) The presence of error-prone strands (light orange)with highmutation and
recombination rates can also lead to an erroneous association. Here we ob-
served that 3/7 (43%) recombined regions contain a mutation and that 5/17
(29%) nonrecombined regions contain a mutation. However, there are no
mutations in recombined regions outside the error-prone strands, and in the
error-prone strands, there are a total of 3/4 regions mutated in both the re-
combined and nonrecombined regions.
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these intervals so that NRR is less than NRNR. Upon analysis, we
found that the mutation rate in nonrecombined intervals in
strands with recombination was lower than the rate on strands
without recombination (NRR  NRNR; P  0.004 by using the
reshuffling approach). This indicates that the association between
recombination and mutation was not a product of confounding
effects such as error-prone strands.
This analysis of mutation rates on NRR and NRNR provides a
useful independent verification that neither PCR-induced recom-
bination nor transfection-induced recombination was a factor
driving the association between mutation and recombination;
that is, both PCR-induced and transfection-induced recombina-
tions occur without consideration of whether the virions were
homozygous or heterozygous. Hence, if the associationwas due to
either of these mechanisms, we would expect the rate of mutation
in NRR and NRNR to be the same.
Pattern of mutation in recombined and nonrecombined se-
quences.Given the increasedmutation rates in recombined inter-
vals, we sought to investigate whether the pattern ofmutation in R
intervals was significantly different from that in NR intervals. Be-
cause many NR intervals have come from homozygous virions
and thus have undetected recombination, we compared muta-
tions in nonrecombined intervals from recombined sequences
(NRR, where any odd number of recombination events should
have been detectable). We found no substantial differences in the
patterns of mutation observed in NRR and recombined sequences
(Table 4).
Recombination and frameshift mutations. The above-de-
scribed results have analyzed the rate of substitution mutations.
However, it has also been suggested that recombination may be
associated with insertions and deletions (indels) (59). To investi-
gate this, we performed the same analysis as that described above
to investigate whether the indel rate was higher in R or NR inter-
vals (Table 2). Although we observed a trend toward higher rates
of indels in recombined sequences (6.989 versus 6.572 indels per
1,000 nt), this was not significant by using a two-tailed permuta-
tion test (P 0.31). One reason for the inability to demonstrate a
consistent significant difference in indel rates is the high back-
ground indel rate due to the difficulties in identifying homopoly-
mer lengths during 454 sequencing (60). Indeed, the rate of indels
of the DNA control is higher than that of the experimental se-
quences (6.694 versus 6.589 indels per 1,000 nt; P  0.028 by
Fischer’s exact test). The 454 sequencing indels in theDNA sample
are preferentially clustered around longer homopolymer tracts.
Thus, we filtered the indel detection algorithm to exclude indels
arising from homopolymer tracts of3 nt. This reduced the indel
rate in both R and NR sequences, although the difference was still
not significant (P 0.21 by two-tailed permutation test).
One issue with comparing all intervals with observed recom-
bination with all intervals with no observed recombination is that
the latter intervals include homozygous sequences in which silent
recombination (and the associated rate of mutation) occurred on
a homozygous virion and so was not observable. Thus, including
these “silently recombined” sequences in the nonrecombined
group will push up the observed mutation rate. In order to try to
exclude this, we can limit our analysis to nonrecombined regions
that were observed on recombined sequences (NRR); that is, be-
cause recombination was observed elsewhere on a sequence, we
know that the sequence came from a heterozygous virion, and
thus, silent recombination was not possible. The indel rate in R
was significantly higher than the indel rate in NRR (6.989 versus
6.265 indels per 1,000 nt; P  0.0464 by two-tailed permutation
test). Additionally, when the data were filtered to eliminate indels
from homopolymers (a limitation of 454 pyrosequencing) of3
nt, the recombination rate in R was significantly higher than that
in NRR (2.02 versus 1.55; P  0.003 by two-tailed permutation
test). While the rate of indels is significantly higher in R than in
NRR sequences, the high background rate of indels complicates
the analysis.
DISCUSSION
Genetic diversity inHIV arises primarily during reverse transcrip-
tion via the introduction of mutations that are then shuffled be-
tween viral genomes by recombination. It is generally thought that
FIG 3 Permutation of recombination and mutation sites. An excess of
mutations in recombined regions can be produced simply by having re-
gions of the genome with high mutation and recombination rates (coinci-
dent hot spots) (Fig. 2A). To overcome this, we performed a permutation
test as follows. (A) We classified each interval on each sequence to be
recombined and/or mutated. (B) With each reshuffle, the recombination
status of intervals was randomly permuted. To eliminate confounding fac-
tors (such as coincident hot spots), recombination status is permuted only
within the same interval, amplicon, direction of sequencing, and patient.
Reshuffling 10,000 times generates the distribution of mutation rates that
would occur if recombination and mutation were not mechanistically as-
sociated. Statistics were calculated by comparing the original unpermuted
data with the generated null distribution.
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recombination and mutation are not associated, although previ-
ous studies addressing this question have led to conflicting results
(28–30). In this study, we have employed a novel HIV marker
system and a high-throughput pyrosequencing system to simul-
taneously measure mutation and recombination rates directly on
an authenticHIV-1 genome.Our comprehensive analysis demon-
strates that recombination is associated with point mutations in
HIV infection of primary T cells.
Three previous studies have attempted to evaluate the poten-
tial linkages between recombination andmutation in retroviruses
(28–30). In the first two studies, 65,000 and 4,100 bp were se-
quenced in a spleen necrosis virus (SNV) vector andHIV genomes
(with 2 and 0.1 anticipated mutation events), yet 0 and 2 muta-
tions were detected, respectively, leading the authors of those
studies to conclude that any association was absent or uncertain
(28, 29). In a third study, a larger analysis was carried out in which
five recombined sequences were observed to contain substitution
mutations, leading those authors to conclude that around 6% of
recombination resulted inmutation (30). However, those authors
pointed out that the background mutation rate of that study was
four times higher than expected. Moreover, the estimated rate of
recombination-associatedmutation would lead to a higher muta-
tion rate in HIV than theoretically possible, even if it was the only
source of mutation and excluding other mechanisms, such as
APOBEC-mediated mutations; that is, if there is a 6% chance of
mutation per recombination, and HIV undergoes 5 to 15 recom-
bination events per genome (20, 35, 45), this would lead to 0.3 to
0.9 mutation-associated recombinations per genome. However,
only
0.3 to 0.4mutations are usually observed (2, 19), suggesting
that this rate is higher than what is compatible with the observed
mutation rates. Those authors speculate that this high level of
mutation might result from the two rounds of reverse transcrip-
tion and subsequent PCR (30). With these higher-than-expected
mutation rates and the potential confounding recombination
events (30), it is difficult to utilize the data set to determine the
potential linkage between retroviralmutation and recombination.
In the current study, we analyzed over 27 million nt of se-
quencing data (including 7 million nt of a viral genome from a
heterozygous HIV infection) and observed 859 mutations and
4,801 recombination events during HIV infection. Using this sys-
tem, we found an overall mutation rate of 0.0458 mutations per
1,000 nt per replication cycle and a recombination rate of 1.51
events per 1,000 nt per replication cycle, which are similar to the
rates previously reported for HIV-1. Furthermore, using appro-
priate controls and statistical analyses, we demonstrated that this
association betweenmutation and recombination represents a bi-
ological association rather than experimental or statistical arti-
facts.
The association between recombination and mutation can be
explained in three ways: mutation increases the chance of recom-
bination, recombination increases the chance of mutation, or the
chance of individual mutation and recombination events can be
influenced simultaneously by some other factor. Our analysis can-
not identify the direction of causality. However, if the direction is
such that mutation increases the chance of recombination, the
effect of each mutation on the overall recombination rate will be
minimal, as the mutation rate is approximately 100-fold lower
than the recombination rate. Conversely, as recombination occurs
much more frequently than mutation, if recombination influ-
ences mutation, this may have a significant impact on the overall
mutation rate and mutation hot spots.
Assuming the scenario where recombination increases the
probability ofmutation, we calculated what combination of back-
groundmutation rate per nucleotide and additionalmutation rate
per recombination event best fits the experimental data, thus es-
timating the proportion of mutations that are attributable to re-
combination. Using the overall rate of recombination and the
rates of mutation in R, NRNR, and NRR sequences, we used two
mathematical methods to calculate the recombination-induced
mutation rate. After subtracting the recombination-associated
mutation rates from sequencing and PCR, we found that each
viral recombination has a 0.5 to 0.6% chance of inducing a muta-
TABLE 4 Mutation pattern of recombined and nonrecombined intervalsa
Original nucleotide No. of nucleotides
% (no.) of mutated
sequences (105)
% (no.) of nucleotide mutations out of total mutations
A C G T
Recombined interval
A 111,789 8.1 (9) 0 3.7 (2) 13.0 (7) 0.0 (0)
C 56,088 12.5 (7) 3.7 (2) 0 1.9 (1) 7.4 (4)
G 66,473 45.1 (30) 46.3 (25) 3.7 (2) 0 5.6 (3)
T 63,558 12.6 (8) 5.6 (3) 5.6 (3) 3.7 (2) 0
Nonrecombined interval from
recombined sequence
A 220,054 5.0 (11) 0 4.7 (2) 20.9 (9) 0.0 (0)
C 101,042 4.9 (5) 0.0 (0) 0 2.3 (1) 9.3 (4)
G 124,497 16.9 (21) 41.9 (18) 0.0 (0) 0 7.0 (3)
T 125,032 4.8 (6) 0.0 (0) 11.6 (5) 2.3 (1) 0
Plasmid DNA control
A 1,892,627 4.9 (99) 0 1.1 (4) 20.8 (76) 4.4 (16)
C 883,997 12.4 (117) 5.7 (21) 0 2.2 (8) 20.8 (76)
G 1,074,185 11.4 (131) 25.4 (93) 0.5 (2) 0 6 (22)
T 1,080,207 4.5 (52) 1.9 (7) 10.7 (39) 0.5 (2) 0
a The frequencies of substitution mutations in A, C, G, and T as well as the nucleotide to which the nucleotide is mutated are indicated for recombined intervals and for
nonrecombined intervals from recombined sequences. These mutation patterns are the cumulative product of experimental factors (such as sequencing error) and viral factors. To
give some indication of the contribution of sequencing error to the pattern seen, the frequency of substitution mutations in the plasmid DNA control is shown.
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tion in the same interval. This corresponds to viral recombination
inducing approximately 0.07 to 0.09 mutations per genome (of
9,600 bp in length), representing between 15% and 20% of all
virus-associated mutations.
One plausible explanation for this observation is that recom-
bination is mutagenic and, thus, that mutations are introduced
into the viral genome at the site of recombination (24, 26, 27, 61).
Indeed, early in vitro investigations showed that HIV-1 RT fre-
quently adds nontemplated nucleotides at the 3= ends of nascent
DNA during reverse transcription and that these nontemplated
nucleotides are misincorporated upon strand transfer (25, 27). In
support of this mechanism, the mutation rate for murine leuke-
mia virus (MLV), a related retrovirus, was reported to be 1,000-
fold higher at the site of first-strand transfer than in other regions
of the genome (62). However, in vitro recombination and first-
strand transfer occur at template ends, and it is not known
whether this corresponds to recombination at internal positions
within the genome analyzed in that study. It was reported that a
nontemplated addition is highly specific for purines (A 	 G 		
T		 C), yet there was no difference in the mutation spectra ob-
served between recombined and nonrecombined intervals. This
suggests that this mechanism of mutagenic recombination does
not take place or that the mutation spectrum during a natural
infection cycle is different from that observed in vitro. Another
mechanism of mutation at recombination sites is referred to as
“slippage synthesis” (24). This occurs due to the misalignment of
the 3= end of the nascent DNA onto the acceptor RNA template.
This type of recombination-inducedmutagenesis is expected to be
highly dependent on local sequence characteristics of the tem-
plate. Indeed, one in vitro study demonstrated that while one re-
combination location was associated with a 30% mutation rate,
another recombination location was not associated with muta-
tions (21). Differences in template sequence may explain why
some studies support the notion that recombination causes mu-
tation (21, 24, 25) whereas other studies do not (63). One impor-
tant advantage of our system is that mutation and recombination
rates are measured directly on the HIV-1 genome, meaning that
these results are not biased by foreign gene sequences.
Another explanation for the association betweenmutation and
recombination is that mutation increases the likelihood of tem-
plate switching, rather than template switching being mutagenic
(22, 23, 64). HIV-1 RT is capable of extending mismatched tem-
plate primers, but this extension is associated with pausing of
DNA synthesis (22). The most widely accepted model for retrovi-
ral recombination, the dynamic copy choice model, suggests that
the rate of recombination is determined by the dynamic steady
state between DNA polymerase and RNase H activities (65). This
model predicts that increasing the RNase H-to-polymerase ratio
by stalling DNA synthesis will increase the local rate of recombi-
nation. In agreement with this model, synthesis from a mis-
matched primer increased strand transfer by 50% compared to a
complementary primer, and this was associated with a significant
pause in synthesis (22, 23). Furthermore, in an in vitro template-
switching assay, a lower frequency of mutations was observed on
the donor template when in the presence of an acceptor template,
implying that mutation induces template switching onto the ac-
ceptor (64).
In this study, the direction of causality is unclear. Indeed, it is
plausible that recombination-induced mutation and mutation-
induced recombination are both responsible for the observed as-
sociation. Regardless of the causality, our study demonstrates a
direct linkage between recombination and mutation in driving
overall viral evolution. In the event that the association is due only
to recombination-induced mutation, our calculations show that
up to 20% of mutations result from recombination. It is unclear
whether the observed association between mutation and recom-
bination provides an evolutionary advantage to the virus or is
simply a result of the mechanisms of transcription of the error-
prone RT. Given the importance of recombination and mutation
to the evolution of drug resistance and immune escape, dissecting
parameters andmolecular determinants that regulate these events
will be vital to define the process of HIV evolution. Such informa-
tion is likely to be invaluable for understanding the emergence of
immune escape and antiviral drug-resistant HIV in the course of
HIV infection and AIDS pathogenesis.
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